Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Melanoma × fludarabine × Clear all

Phase

Phase 2 21 Phase 1 21 Phase 1/2 15 Phase NA 1 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myeloid, Acute 22 Leukemia, Lymphocytic, Chronic, B-Cell 14 Precursor Cell Lymphoblastic Leukemia-Lymphoma 7 Myelodysplastic Syndromes 7 Lymphoma, Non-Hodgkin 6 Lymphoma, Follicular 5 Multiple Myeloma 4 Leukemia 4 Lymphoma 3 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3 Myeloproliferative Disorders 2 Lymphoma, Mantle-Cell 2 Graft vs Host Disease 2 Venentoclax 1 Sarcoma, Synovial 1 Recurrence 1 Primary Myelofibrosis 1 Neoplasms, Plasma Cell 1 Neoplasm, Residual 1 Melanoma 1 Lymphoma, Large B-Cell, Diffuse 1 Leukemia, Biphenotypic, Acute 1 Burkitt Lymphoma 1 Anemia, Refractory, with Excess of Blasts 1 Anemia 1

Interventions

Dacarbazine 22 Nivolumab 20 pembrolizumab 15 Ipilimumab 15 Interferon-alpha 10 trametinib 7 aldesleukin 7 dabrafenib 6 Vemurafenib 6 Temozolomide 6 Introns 6 Interferon alpha-2 6 Interleukin-2 5 Cisplatin 5 Radiotherapy 4 Chemotherapy, Adjuvant 4 cobimetinib 3 cemiplimab 3 binimetinib 3 Vinblastine 3 Specimen Handling 3 Sodium Chloride 3 Radiosurgery 3 Paclitaxel 3 Opdualag 3 Melphalan 3 Magnetic Resonance Spectroscopy 3 CTLA-4 Antigen 3 technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 2 spartalizumab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02278887 2025-03-10

TIL

The Netherlands Cancer Institute

Phase 3 Completed

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡